Antibe Therapeutics Inc (ATE.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in thousands)
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Cash Flows From Operating Activities | |||||
| Accounts receivable | 57 | -142 | 67 | -109 | -326 |
| Accounts payable and accrued liabilities | N/A | N/A | N/A | -9 | -95 |
| Other Working Capital | -73 | -1,345 | 786 | -537 | -176 |
| Other Operating Activity | -3,829 | -4,945 | -5,437 | -2,729 | -3,008 |
| Operating Cash Flow | $-3,845 | $-6,432 | $-4,584 | $-3,384 | $-3,605 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | N/A | 2 | N/A |
| Net Acquisitions | N/A | N/A | N/A | -240 | 559 |
| Purchase Of Investment | 0 | -3,313 | -10,109 | -10,311 | -10,016 |
| Sale Of Investment | 10,166 | 5,095 | 16,731 | 10,000 | 10,000 |
| Other Investing Activity | 875 | 0 | 0 | 0 | -11 |
| Investing Cash Flow | $11,041 | $1,782 | $6,622 | $-549 | $532 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | 0 | 0 | 0 | 0 | -1 |
| Other Financing Activity | 0 | 0 | 0 | 159 | 0 |
| Financing Cash Flow | $0 | $0 | $0 | $159 | $-1 |
| Beginning Cash Position | 4,143 | 8,793 | 6,755 | 10,529 | 13,603 |
| End Cash Position | 11,339 | 4,143 | 8,793 | 6,755 | 10,529 |
| Net Cash Flow | $7,196 | $-4,650 | $2,038 | $-3,774 | $-3,074 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,845 | -6,432 | -4,584 | -3,384 | -3,605 |
| Free Cash Flow | -3,845 | -6,432 | -4,584 | -3,384 | -3,605 |